M Zweifel
Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse
Gössi F, Schardt J, Bargetzi M, Berthold D, Hess U, Stenner F, Mischo A, Panagiotis S, Zweifel M, Spahn M, Pabst T. Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. Bone Marrow Transplant 2016; 52:334-336.
Nov 28, 2016Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse
Nov 28, 2016Bone Marrow Transplant 2016; 52:334-336
Gössi F, Schardt J, Bargetzi M, Berthold D, Hess Urs, Stenner F, Mischo A, Panagiotis S, Zweifel M, Spahn M, Pabst T
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Leyvraz S, Honegger H, Dietrich D, Fey M, Sessa C, Cerny T, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51.
Apr 1, 2006Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Apr 1, 2006Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51
Leyvraz S, Honegger H P, Dietrich D, Fey M, Sessa C, Cerny Thomas, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research